🎉 M&A multiples are live!
Check it out!

Outlook Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Outlook Therapeutics and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Outlook Therapeutics Overview

About Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.


Founded

2010

HQ

United States of America
Employees

23

Financials

LTM Revenue $4.0M

LTM EBITDA n/a

EV

$70.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Outlook Therapeutics Financials

Outlook Therapeutics has a last 12-month revenue of $4.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Outlook Therapeutics achieved revenue of n/a and an EBITDA of -$72.1M.

Outlook Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Outlook Therapeutics valuation multiples based on analyst estimates

Outlook Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$57.4M -$72.1M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$66.1M -$59.0M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a $12.2M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Outlook Therapeutics Stock Performance

As of April 15, 2025, Outlook Therapeutics's stock price is $1.

Outlook Therapeutics has current market cap of $45.3M, and EV of $70.7M.

See Outlook Therapeutics trading valuation data

Outlook Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$70.7M $45.3M XXX XXX XXX XXX $-2.83

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Outlook Therapeutics Valuation Multiples

As of April 15, 2025, Outlook Therapeutics has market cap of $45.3M and EV of $70.7M.

Outlook Therapeutics's trades at 17.9x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Outlook Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Outlook Therapeutics and 10K+ public comps

Outlook Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $70.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Outlook Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Outlook Therapeutics Valuation Multiples

Outlook Therapeutics's NTM/LTM revenue growth is 523%

Outlook Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.1M for the same period.

Over next 12 months, Outlook Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Outlook Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Outlook Therapeutics and other 10K+ public comps

Outlook Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 26% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Outlook Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Outlook Therapeutics M&A and Investment Activity

Outlook Therapeutics acquired  XXX companies to date.

Last acquisition by Outlook Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Outlook Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Outlook Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Outlook Therapeutics

When was Outlook Therapeutics founded? Outlook Therapeutics was founded in 2010.
Where is Outlook Therapeutics headquartered? Outlook Therapeutics is headquartered in United States of America.
How many employees does Outlook Therapeutics have? As of today, Outlook Therapeutics has 23 employees.
Who is the CEO of Outlook Therapeutics? Outlook Therapeutics's CEO is Mr. Lawrence A. Kenyon.
Is Outlook Therapeutics publicy listed? Yes, Outlook Therapeutics is a public company listed on NAS.
What is the stock symbol of Outlook Therapeutics? Outlook Therapeutics trades under OTLK ticker.
When did Outlook Therapeutics go public? Outlook Therapeutics went public in 2016.
Who are competitors of Outlook Therapeutics? Similar companies to Outlook Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Outlook Therapeutics? Outlook Therapeutics's current market cap is $45.3M
What is the current revenue of Outlook Therapeutics? Outlook Therapeutics's last 12-month revenue is $4.0M.
What is the current EV/Revenue multiple of Outlook Therapeutics? Current revenue multiple of Outlook Therapeutics is 17.9x.
Is Outlook Therapeutics profitable? Yes, Outlook Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.